These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24997578)

  • 21. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A GSH-resistant FK228 analogue containing a stable disulfide bond.
    Zhan MM; Xing Y; Li Z; Yin F
    Bioorg Chem; 2024 Mar; 144():107119. PubMed ID: 38219481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
    Suzuki T; Kouketsu A; Itoh Y; Hisakawa S; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2006 Aug; 49(16):4809-12. PubMed ID: 16884291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
    Huang D; Li X; Sun L; Xiu Z; Nishino N
    J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood.
    Xiao JJ; Byrd J; Marcucci G; Grever M; Chan KK
    Rapid Commun Mass Spectrom; 2003; 17(8):757-66. PubMed ID: 12672127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells.
    Murakami K; Matsubara H; Hoshino I; Akutsu Y; Miyazawa Y; Matsushita K; Sakata H; Nishimori T; Usui A; Kano M; Nishino N; Yoshida M
    Oncology; 2010; 78(1):62-74. PubMed ID: 20215787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
    Shivashimpi GM; Amagai S; Kato T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2007 Dec; 15(24):7830-9. PubMed ID: 17881232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
    Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
    ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrolactamization versus macrolactonization: total synthesis of FK228, the depsipeptide histone deacetylase inhibitor.
    Wen S; Packham G; Ganesan A
    J Org Chem; 2008 Dec; 73(23):9353-61. PubMed ID: 18991384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
    Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
    Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
    Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
    Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
    Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
    Wang H; Zhou W; Zheng Z; Zhang P; Tu B; He Q; Zhu WG
    DNA Repair (Amst); 2012 Feb; 11(2):146-56. PubMed ID: 22112863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
    Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of a potent histone deacetylase inhibitor.
    Liu T; Kapustin G; Etzkorn FA
    J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.